ARG Travels to Support Medical & Biopharma Technology, Oncology and Neurology
July 13, 2023
ARG, with offices in Charlottesville, London, Amsterdam, Steinhausen, Munich, Warsaw and Sydney, is supporting its locations and therapeutic expertise with 2023 travel plans.
Of particular note is the travel associated with ARG’s
medical and biopharma technology focus. ARG CMO Dr. Jeff Lawson, an expert in thrombotic and hemostatic surgical care, recently traveled to Montreal for the 31st Congress of the International Society on Thrombosis and Haemostasis (ISTH).
Later on in the year, an ARG team led by Dr. Lawson will head to New York for the 50th Annual Symposium on Vascular and Endovascular Issues (VEITH). Sponsors are in need of a CRO that understands the nuances that come with surgical and interventional vascular studies, and the team will be there to listen and learn.
To support
oncology in 2023, ARG has already traveled to Orlando for the American Association of Cancer Research (AACR) annual meeting and to Chicago for the American Society of Clinical Oncology (ASCO) meeting. At both conferences, ARG was represented by Dr. Victoria Allgood, Vice President of Scientific Affairs, Oncology, along with Senior Vice President of Business Development Mike Baker and Business Development Associate Kendyl Dixon.
ARG is also committed to
neurology clinical research, and part of the tight-knit ALS community. To demonstrate this commitment, ARG acted as sponsors for both the 2nd ALS Drug Development Summit in Boston in May, and the European Network to Cure ALS (ENCALS) this month in Barcelona.
Dr. Ignazio Di Giovanna, Vice President, Scientific Affairs, Neurology attended both gatherings, joined by Mike Baker and Kendyl Dixon in Boston, and by Faisal Zaman, Director, Project Operations in Barcelona.
Looking forward to October, Dr. Di Giovanna will travel to Florida to the Opal Sands Resort in Clearwater Beach for the 22nd Northeast ALS Consortium (NEALS).
Please read more about ARG including
what makes us different and our mission here.
